ir.inspirepharm.com
Non-Existent DomainYour browser does not support iframes, please click here.
http://ir.inspirepharm.com/
Your browser does not support iframes, please click here.
http://ir.inspirepharm.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Tuesday
LOAD TIME
PAGES IN
THIS WEBSITE
0
SSL
EXTERNAL LINKS
0
SITE IP
0.0.0.0
LOAD TIME
0 sec
SCORE
6.2
Non-Existent Domain | ir.inspirepharm.com Reviews
https://ir.inspirepharm.com
Your browser does not support iframes, please click here.
IRWeblink
Thank you for your interest in IR Solutions. You have reached this page because the URL you have requested is no longer available, or you do not have permission to view it. For more information on the most comprehensive IR web site management tool available, please click here. If you have any questions, e-mail IRSupport@snl.com. Or call (866) 802-9128 and ask for an IR Solutions sales representative. To return to the main SNL Financial homepage.
Investor Relations | Innophos Holdings, Inc.
Skip to main navigation. Innophos is a global specialty ingredients provider with:. An attractive EBITDA profile, and. 725m of revenue in 2016. We have a strong, clearly defined vision for the future called Vision 2022. To deliver on our Vision 2022 goals. Annual revenues: $725 million (FY 2016). Total assets: $643 million (FY 2016). Employs approximately 1,400 people worldwide. Acquired Novel Ingredients in August 2017 and NutraGenesis in November 2017. Innophos IPO date: November 2, 2006.
Investor Overview - Investors - Inotek Pharmaceuticals
Stock Quote and Chart. Inotek Pharmaceuticals Top-line MATrX-1 Results Conference Call. 160;at 8:30 am ET. Inotek Pharmaceuticals Top-line MATrX-1 Results Conference Call. Tuesday, January 3, 2017 . 8:30 am ET . Click here for webcast. Click here to add this event to your calendar. 160;- 0.03. Data as of 01/12/17 4:00 pm ET. Data provided by Nasdaq. Minimum 15 minute delay. Jan 3, 2017. Inotek Announces Top-line Results for MATrX-1, First Phase 3 Trial of Trabodenoson for Glaucoma. Nov 10, 2016.
IR WebSite
Inovio Pharmaceuticals - Investors - Overview
Inovio In The News. Investor News and Media. Financial Reports and Filings. Quarterly and Annual Reports. Code of Business Conduct and Ethics. Board Committee Composition and Charters. Contact the Board of Directors. Investigator Conflict of Interest Policy. Inovio is revolutionizing the fight against cancer and infectious diseases. Inovio Pharmaceuticals to Host Second Quarter 2015 Financial Results Conference Call August 10, 2015. 2Q 2015 Financial Results Conference Call. August 10, 2015. 660 West Ger...
IRWeblink
Thank you for your interest in IR Solutions. You have reached this page because the URL you have requested is no longer available, or you do not have permission to view it. For more information on the most comprehensive IR web site management tool available, please click here. If you have any questions, e-mail IRSupport@snl.com. Or call (866) 802-9128 and ask for an IR Solutions sales representative. To return to the main SNL Financial homepage.
Press Releases - Inteliquent
Direct Inward Dial (DID). Law Enforcement and Subpoenas. 10 results per page. 25 results per page. 50 results per page. GTCR Completes Acquisition of Inteliquent. File is in Briefcase. Inteliquent Reports Third Quarter 2016 Results. Financial and operating highlights include: Company agrees to be acquired by GTCRCompany invests in Zipwhip, a Seattle-based business texting SaaS companyThird quarter 2016 minutes of use increased 55.0% compared to third quarter of 2015Third quarter 2016 revenue increa.
Intellia Therapeutics - Investor Relations
Intellia is a leading genome editing company, focused on the development of potentially curative therapeutics utilizing the CRISPR/Cas9 system. The Company’s mission is to develop gene editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. January 11, 2017. Intellia Therapeutics Joins Genomics England’s Industry Consortium. December 16, 2016. December 13, 2016. Intellia Therapeutics Names Graeme Bell Chief Financial Officer. Trout Group, LLC.
Investors - Intercept Pharmaceuticals, Inc.
4:00 PM ET on Aug 14, 2015. Delayed at least 20 minutes. Aug 5, 2015. Intercept Pharmaceuticals Reports Second Quarter 2015 Financial Results and Provides Business Update. Jul 29, 2015. Intercept to Report Second Quarter 2015 Financial Results on August 5 and Present at Upcoming Conferences. View all press releases. Recent Events and Presentations. Aug 11, 2015 at 10:55 AM ET. 2015 Wedbush PacGrow Healthcare Conference. Aug 5, 2015 at 4:30 PM ET. Second Quarter 2015 Financial Results and Conference Call.
